Abstract
S100A8 and S100A9 proteins are highly upregulated in patients with psoriasis and have been proposed as potential biomarkers for psoriasis. The present study was designed to analyze the effect of narrowband ultraviolet B therapy on these proteins.S100A8, S100A9 gene expression and S100A8/A9 heterocomplex protein levels were analyzed in lesional and non-lesional skin before and after narrowband-UVB treatment in patients with chronic plaque type psoriasis. In addition, disease severity was measured by psoriasis area and severity index (PASI) and serum protein levels of S100A8/A9 were repeatedly analyzed. Narrowband-UVB treatment significantly reduced S100A8, S100A9 gene expression and S100A8/A9 protein levels in lesional skin while serum levels showed no significant change. No correlation between PASI and serum S100A8/A9 protein levels was found. These results implicate a role of S100A8/A9 in the anti-inflammatory effect of narrowband-UVB. Serum S100A8/A9 levels do not respond to treatment suggesting that serum S100A8/A9 does not originate from psoriasis skin keratinocytes. Serum S100A8/A9 levels do not correlate with PASI questioning serum S100A8/A9 as a biomarker for psoriasis skin activity.Trial Registration: DRKS 00014817.
Highlights
S100A8 and S100A9 gene expression in lesional skin was significantly elevated compared to non-lesional skin before start of NB-UVB treatment (Figs 2 and 3)
Gene expression results were consistent with skin protein expression of S100A8/A9, which showed a significant decrease after NB-UVB (Fig 4)
The present study shows for the first time that NB-UVB treatment significantly suppress elevated S100A8/A9 protein heterocomplex levels in lesional skin to levels comparable to those found in non-lesional skin
Summary
The S100A8/S100A9 heterocomplex (calprotectin) is composed of S100A8 and S100A9 proteins ( termed MRP8 and MRP14) and are subgroups of the S100 calgranulin family [1, 2]. S100A8 and S100A9 are exceedingly upregulated in the epidermis in lesional skin of patients with psoriasis [13] and histopathological analysis of psoriatic lesions show increased levels of S100A8/A9 in keratinocytes compared to healthy skin [15,16,17] These findings led to the assumption that S100A8 and S100A9 might be potential therapeutic targets for the treatment of psoriasis [15]. Previous genomic transcriptome studies on the effect of NB-UVB in psoriasis showed downregulation of S100A8 and S100A9 in response to NB-UVB [18, 19] These studies included only 3 and 11 patients and did not analyse protein expression. The correlation between psoriasis area and severity index (PASI) and serum levels was studied to investigate a potential role of serum S100A8/A9 as a biomarker for skin disease severity
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
